Minims Oxybuprocaine Chlorhydrate Bausch + Lomb Ireland Limited (Oxybuprocaine Hydrochloride)

Oxybuprocaine hydrochloride is used as a topical ophthalmic anesthetic for procedures involving the anterior segment of the eye.

• Diagnostic ocular procedures (e.g., tonometry, slit‑lamp examination): provides temporary corneal anesthesia to enable accurate measurement and visualization.
• Minor ocular surgeries (e.g., foreign body removal, corneal abrasion debridement): facilitates painless manipulation of ocular tissues.
• Pre‑operative preparation for intra‑ocular injections: ensures patient comfort during intravitreal or anterior chamber drug delivery.

• Oxybuprocaine hydrochloride exerts its effect by reversibly blocking voltage‑gated sodium channels in peripheral nerve membranes of the corneal epithelium. This inhibition prevents the initiation and propagation of action potentials, thereby producing rapid, localized loss of sensation without affecting deeper ocular structures. The blockade is concentration‑dependent and reversible, allowing normal sensation to return within minutes after the drug is cleared from the ocular surface.

Topical ocular application of oxybuprocaine may be associated with transient local reactions and, rarely, more serious ocular events.

Common Side Effects

• Burning or stinging sensation: brief discomfort upon instillation.
• Temporary blurred vision: resolves as the drug clears.
• Mild conjunctival redness: transient hyperemia that subsides within an hour.

Serious or Rare Side Effects

• Corneal epithelial toxicity: persistent ulceration or delayed healing.
• Allergic contact keratitis: inflammation due to hypersensitivity.
• Severe allergic reaction: systemic signs such as rash or angioedema.

When using oxybuprocaine ophthalmic solution, several precautions should be observed to ensure safety and efficacy.

• Contraindication in known hypersensitivity: avoid use in patients with documented allergy to oxybuprocaine or related anesthetics.
• Avoid prolonged exposure: limit application to the shortest duration required for the procedure.
• Use with caution in compromised corneas: patients with epithelial defects or keratitis may experience delayed healing.
• Monitor intra‑ocular pressure: especially in glaucoma patients, as transient pressure changes can occur.
• Do not combine with other topical anesthetics: concurrent use may increase risk of corneal toxicity.
• Store below 25°C: keep in the original container, protect from moisture and light.

Oxybuprocaine may interact with certain ocular or systemic agents; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Concurrent use of other topical ocular anesthetics: additive toxicity to corneal epithelium.
• Systemic sodium channel blockers (e.g., antiarrhythmics): may potentiate local anesthetic effects.
• Anticholinergic eye drops: can reduce drug clearance, increasing exposure.

Moderate Interactions (Monitor Closely)

• Preservative‑containing eye drops: may enhance irritation when used sequentially.
• Antifungal or antiviral ophthalmic solutions: monitor for delayed wound healing.
• Beta‑blocker eye drops: observe for potential additive intra‑ocular pressure effects.